ライフサイエンスコーパス: chronic kidney disease

1 th chronic inflammation, including anemia of chronic kidney disease.

2 ibrosis in tissue samples from patients with chronic kidney disease.

3 ne and in human donors of kidney tissue with chronic kidney disease.

4 , increasing age, diabetes, hypertension and chronic kidney disease.

5 naemia and states of FGF23 excess, including chronic kidney disease.

6 n obesity and rheumatoid arthritis, and 2 on chronic kidney disease.

7 sed to diagnose and classify the severity of chronic kidney disease.

8 ith acute kidney injury or those at risk for chronic kidney disease.

9 associated with multiple diseases, including chronic kidney disease.

10 te levels are associated with progression of chronic kidney disease.

11 ce interval: 1.16, 1.74) among patients with chronic kidney disease.

12 ation is essential to prevent progression to chronic kidney disease.

13 erm profibrotic responses that could lead to chronic kidney disease.

14 isk of renal events than in patients without chronic kidney disease.

15 nephropathy has altered the epidemiology of chronic kidney disease.

16 in modulating pruritus in conditions such as chronic kidney disease.

17 ease, stroke, peripheral artery disease, and chronic kidney disease.

18 incomplete or maladaptive kidney repair and chronic kidney disease.

19 ular and total mortality, and progression of chronic kidney disease.

20 er renal IRI, thus preventing progression to chronic kidney disease.

21 nting for ~5% of monogenic disorders causing chronic kidney disease.

22 ed numbers of patients with high CV risk and chronic kidney disease.

23 or follow AKI in a continuum with acute and chronic kidney disease.

24 ment for metabolic acidosis in patients with chronic kidney disease.

25 ndrial energy metabolism may be causative to chronic kidney disease.

26 with type 2 diabetes and moderate-to-severe chronic kidney disease.

27 ut prior heart failure or moderate to severe chronic kidney disease.

28 t baseline was a better predictor of time to chronic kidney disease.

29 glomerular filtration rate in patients with chronic kidney disease.

30 ll-known clinical biomarker for the onset of chronic kidney disease.

31 d predicts accelerated functional decline in chronic kidney disease.

32 hypertension, type 2 diabetes mellitus, and chronic kidney disease.

33 s in two cohorts totaling 3315 patients with chronic kidney disease.

34 tage kidney disease, even at early stages of chronic kidney disease.

35 mediated by the known APOL1 association with chronic kidney disease.

36 which serves as a critical factor leading to chronic kidney disease.

37 on, treatment with ferric carboxymaltose and chronic kidney disease.

38 ncreased risk of developing hypertension and chronic kidney disease.

39 have routinely excluded those with advanced chronic kidney disease.

40 key biomarker for cardiovascular disease and chronic kidney disease.

41 population with type 2 diabetes and advanced chronic kidney disease.

42 ve therapies for the management of acute and chronic kidney disease.

43 diagnosis and prognostication for acute and chronic kidney diseases.

44 ns, sepsis, and ischemia/reperfusion, and in chronic kidney diseases.

45 eir damage contributes to the progression of chronic kidney diseases.

46 ase (1.3 [1.3-1.4]), stroke (2.2 [2.1-2.2]), chronic kidney disease (1.7 [1.7-1.8]), and peripheral a

47 emia (72.1%), diabetes mellitus (31.6%), and chronic kidney disease (28.2%); 20.2% received warfarin

48 disease, 12.8% (n=59), cancer, 11.7% (n=54), chronic kidney disease, 3.9% (n=18) and inflammatory bow

49 disease 1.6 (1.5-1.7), stroke 6.4 (6.3-6.5), chronic kidney disease 4.4 (4.3-4.6), and peripheral art

50 le on-switches in gene therapy for anemia of chronic kidney disease(6), we demonstrated regulated exp

51 Chronic kidney disease (89% vs 57% P = .0007), diabetes

52 Chronic kidney disease affects >15% of the U.S. populati

53 Chronic kidney disease affects 10% of the population wit

54 = 0.004), hypertension, hyperlipidemia, and chronic kidney disease (all p < 0.001).

55 e, moderate or severe ischemia, and advanced chronic kidney disease (an estimated glomerular filtrati

56 Among patients with chronic kidney disease, an untargeted serum metabolomics

57 In patients with chronic kidney disease and a high risk of progression, u

58 ture mortality from substance use disorders, chronic kidney disease and acute glomerulonephritis, and

59 Albuminuria acts as a marker of progressive chronic kidney disease and as an indicator for initiatio

60 metabolic acidosis including progression of chronic kidney disease and bone health.

61 ract (CAKUTs) represent the leading cause of chronic kidney disease and end-stage kidney disease in c

62 requently reported in patients with advanced chronic kidney disease and is associated with early allo

63 ments are determined in patients with stable chronic kidney disease and may not translate to patients

64 hypertension, obesity, diabetes mellitus and chronic kidney disease and might contribute to disease b

65 e randomly assigned adults with stage 3 or 4 chronic kidney disease and no history of gout who had a

66 accumulate during aging, diabetes mellitus, chronic kidney disease and other chronic diseases.

67 Conclusion For patients with chronic kidney disease and small renal tumors, personali

68 and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes with optimize

69 Among patients with chronic kidney disease and type 2 diabetes, finerenone r

70 weight, the risk of developing or worsening chronic kidney disease and/or atherosclerotic cardiovasc

71 ardiovascular disease (CVD) in patients with chronic kidney diseases and rheumatologic disorders.

72 athies, obesity, hypertension, diabetes, and chronic kidney disease) and yielded additional insights

73 stolic hypertension, -10.1 +/- 20.3 mm Hg in chronic kidney disease, and -10.0 +/- 19.1 mm Hg in atri

74 = 1.2-2.1 for >80 g/day), as were diabetes, chronic kidney disease, and end-stage liver disease (HR

75 ion such as in those with diabetes mellitus, chronic kidney disease, and high risk of future atherosc

76 Higher age, chronic kidney disease, and higher Charlson score increa

77 ients with stable coronary disease, advanced chronic kidney disease, and moderate or severe ischemia,

78 ion in the general population, patients with chronic kidney disease, and patients with heart failure.

79 Diabetes is a leading cause of chronic kidney disease, and the high prevalence of sympa

80 th peptic ulcer disease, depression, asthma, chronic kidney disease, and venous thromboembolism.

81 ociated with PH among patients with advanced chronic kidney disease appears to differ by etiology.

82 rbid conditions, including heart failure and chronic kidney disease, are increasingly prevalent in pa

83 athogenesis of acute kidney injury (AKI) and chronic kidney disease, as well as in abnormal kidney re

84 In a subgroup of patients with advanced chronic kidney disease at baseline (estimated glomerular

85 Chronic kidney disease at baseline was noted in 29% of p

86 Identification of people with diabetes and chronic kidney disease at high-risk of early mortality i

87 ngth (per mm; beta = -1.54), and presence of chronic kidney disease (beta = -1.49) were significantly

88 We found differences in incidence of chronic kidney disease between clusters; however, estima

89 y as a surrogate endpoint for progression of chronic kidney disease, but empirical evidence to suppor

90 Th17 cells play a role in the progression of chronic kidney disease, but the endogenous pathways that

91 relationship between periodontal disease and chronic kidney disease, but there is little evidence to

92 , the use of spironolactone in patients with chronic kidney disease can be restricted by hyperkalaemi

93 te risk equations for outcomes and develop a chronic kidney disease-cardiovascular disease (CKD-CVD)

94 Metabolic acidosis, a complication of chronic kidney disease, causes protein catabolism and bo

95 heart failure, peripheral vascular disease, chronic kidney disease, chronic obstructive pulmonary di

96 disease (OR 3.43, 95% CI 1.17 to 10.00), and chronic kidney disease (CKD) (OR 2.81, 95% CI 1.97 to 4.

97 Our primary outcome was chronic kidney disease (CKD) - defined as confirmed decr

98 Chronic kidney disease (CKD) affects ~10% of the global

99 Transition to chronic kidney disease (CKD) after an episode of acute k

100 A high proportion of patients develop chronic kidney disease (CKD) after liver transplantation

101 Chronic kidney disease (CKD) and aortic stenosis (AS) sh

102 Patients with chronic kidney disease (CKD) and coincident heart failur

103 M(2.5)) is associated with increased risk of chronic kidney disease (CKD) and diabetes, a causal driv

104 Associations between chronic kidney disease (CKD) and the gut microbiota have

105 in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes.

106 Persons with chronic kidney disease (CKD) are at high risk of infecti

107 Adults with chronic kidney disease (CKD) are hospitalized more frequ

108 rtality (ACM), but data at earlier stages of chronic kidney disease (CKD) are inconclusive.

109 ic features implicated in the progression of chronic kidney disease (CKD) are interstitial fibrosis a

110 Patients with chronic kidney disease (CKD) are often 25(OH)D(3) and 1,

111 nd C-reactive protein (CRP) in patients with chronic kidney disease (CKD) are presented.

112 y protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease in

113 re categorized by the presence or absence of chronic kidney disease (CKD) at baseline (estimated glom

114 d subnetworks that potentially differentiate chronic kidney disease (CKD) by severity or progression.

115 Although often considered a single-entity, chronic kidney disease (CKD) comprises many pathophysiol

116 The Japan Chronic Kidney Disease (CKD) Database (J-CKD-DB) is a la

117 Patients with chronic kidney disease (CKD) exhibit reduced exercise ca

118 Chronic kidney disease (CKD) has a rapidly rising global

119 lance and whether their activities change in chronic kidney disease (CKD) has not yet been elucidated

120 Patients with chronic kidney disease (CKD) have inability to maintain

121 Chronic kidney disease (CKD) in low-resource settings po

122 lar disease (ASCVD), heart failure (HF), and chronic kidney disease (CKD) in the ARIC Study.

123 It is hypothesized that chronic kidney disease (CKD) induces oxidant stress whic

124 Chronic kidney disease (CKD) is a common complication of

125 Chronic kidney disease (CKD) is a global health epidemic

126 Chronic kidney disease (CKD) is a growing health burden

127 Chronic kidney disease (CKD) is a major risk factor for

128 Rac promotes tubulointerstitial fibrosis and chronic kidney disease (CKD) is currently unknown.

129 Chronic kidney disease (CKD) is deemed to be a worldwide

130 Data on PCSK9 inhibition in chronic kidney disease (CKD) is limited.

131 Chronic kidney disease (CKD) is responsible for a public

132 Chronic kidney disease (CKD) is the 16th leading cause o

133 linical risk factors, and antiretrovirals to chronic kidney disease (CKD) is unknown.

134 ed with increased mortality and morbidity in chronic kidney disease (CKD) patients, especially in the

135 ophan has been associated with lower risk of chronic kidney disease (CKD) progression, implicating me

136 ssed in the kidney, but its possible role in chronic kidney disease (CKD) remains largely unknown.

137 e (SIHD) who have type 2 diabetes (T2DM) and chronic kidney disease (CKD) remains unclear.

138 The increasing prevalence of chronic kidney disease (CKD) seriously is threatening hu

139 roke), and safety were analyzed according to chronic kidney disease (CKD) stage estimated from CKD-ep

140 urpose of this study was to assess change in chronic kidney disease (CKD) stage following TAVR, ident

141 exemplify this data integration issue for a chronic kidney disease (CKD) study, comprising complex c

142 Chronic kidney disease (CKD) substantially increases the

143 r filtration rate (eGFR) in individuals with chronic kidney disease (CKD) to predict the risk of end

144 rare, hereditary cause of kidney stones and chronic kidney disease (CKD) which is characterized by 2

145 Chronic kidney disease (CKD) with type 2 diabetes (T2D)

146 y injury (AKI) within 3 months and new-onset chronic kidney disease (CKD) within 1 year following hos

147 atients with heart failure (HF) and advanced chronic kidney disease (CKD), a population underrepresen

148 diabetes duration, retinopathy, nephropathy, chronic kidney disease (CKD), and anaemia as predictors

149 Hyperuricaemia is common among patients with chronic kidney disease (CKD), and increases in severity

150 eous ablation for risk factors for worsening chronic kidney disease (CKD), and otherwise PN; biopsy,

151 in conditions such as diabetes mellitus and chronic kidney disease (CKD), and they may be involved i

152 rare, hereditary cause of kidney stones and chronic kidney disease (CKD), characterized by 2,8-dihyd

153 Chronic kidney disease (CKD), commonly fostering nonrena

154 Women with a diagnosis of chronic kidney disease (CKD), CVD, hypertension, or diab

155 y virus (HIV) infection have higher risk for chronic kidney disease (CKD), defined by a reduced estim

156 Chronic kidney disease (CKD), defined by low estimated g

157 gest new treatments for more common forms of chronic kidney disease (CKD), demonstrating the importan

158 lied to a range of human diseases, including chronic kidney disease (CKD), epilepsy, and amyotrophic

159 Felids have a high incidence of chronic kidney disease (CKD), for which the most common

160 he aetiology of cardiometabolic diseases and chronic kidney disease (CKD), in part via metabolism of

161 ally relevant to metabolic diseases, such as chronic kidney disease (CKD), in which dietary approache

162 Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of

163 ted retinopathy and modestly associated with chronic kidney disease (CKD), peripheral artery disease

164 In animal models of chronic kidney disease (CKD), re-activation of BMP signa

165 In patients with chronic kidney disease (CKD), reverse left ventricular (

166 and creatinine is an important biomarker for chronic kidney disease (CKD), we tested the FOLP probe f

167 An estimated glomerular filtration rate by chronic kidney disease (CKD)-EPI-CysC-creatinine <60 mL/

168 perphosphatemia as in tumoral calcinosis and chronic kidney disease (CKD).

169 M1A and PTEN emerged as novel suppressors of chronic kidney disease (CKD).

170 equisite for effective therapy in preventing chronic kidney disease (CKD).

171 kidney failure or death in individuals with chronic kidney disease (CKD).

172 ertrophy, and fibrosis, is a complication of chronic kidney disease (CKD).

173 a modifiable risk factor for progression of chronic kidney disease (CKD).

174 material for MR angiography for safe use in chronic kidney disease (CKD).

175 is activity in acute kidney injury (AKI) and chronic kidney disease (CKD).

176 on (MAC) is a common outcome in diabetes and chronic kidney disease (CKD).

177 in the United States-37 million persons-have chronic kidney disease (CKD).

178 troke (ST), cardiovascular disease (CVD) and chronic kidney disease (CKD).

179 etiology of secondary hyperparathyroidism in chronic kidney disease (CKD).

180 in skin is a common symptom in patients with chronic kidney disease (CKD).

181 ery disease, cancer, liver-, rheumatic-, and chronic kidney disease (CKD).

182 f drug-induced acute kidney injury (AKI) and chronic kidney disease (CKD).

183 baclofen to encephalopathy in patients with chronic kidney disease (CKD).

184 on absorption, and amelioration of anemia in chronic kidney disease (CKD).

185 ith atherosclerotic disease in patients with chronic kidney disease (CKD).

186 es a phenotype strikingly similar to that of chronic kidney disease (CKD).

187 ility and is commonly found in patients with chronic kidney disease (CKD).

188 ed number of older LT recipients with pre-LT chronic kidney disease (CKD).

189 te kidney injury [AKI] and atrophy-fibrosis [chronic kidney disease (CKD)] and rejection.

190 ssion models and stratified for diabetes and chronic kidney disease (CKD, defined as estimated glomer

191 intervals: 0.07% overall, 0.2% for stage 5D chronic kidney disease [CKD], 0.5% for stage 5 CKD and n

192 Chronic kidney diseases (CKDs) are currently classified

193 Clearance of 25-hydroxyvitamin D in Chronic Kidney Disease (CLEAR), NCT02937350; Clearance o

194 betes in coronary artery disease, stroke and chronic kidney disease, complemented by a systematic rev

195 e aimed to investigate the relations between chronic kidney disease, coronary microvascular dysfuncti

196 Most forms of chronic kidney disease culminate in renal fibrosis that

197 y: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease (DD), NCT02875886.

198 and analyze the association between AKI and chronic kidney disease (defined as at least mildly decre

199 tients with atrial fibrillation and advanced chronic kidney disease (defined as creatinine clearance

200 e/incidence of cardiovascular disease (CVD), chronic kidney disease, depression, diabetes, high total

201 specific expression of genes associated with chronic kidney disease, diabetes and hypertension, provi

202 ailure, peripheral arterial disease, asthma, chronic kidney disease, diabetes or COPD in the 12 month

203 and atherosclerosis), comorbidities (anemia, chronic kidney disease, diabetes, and so on), and diseas

204 isk were most sensitive to the prevalence of chronic kidney disease, diabetes, cardiovascular disease

205 ailure, peripheral arterial disease, asthma, chronic kidney disease, diabetes, or COPD in the 12 mont

206 and/or myocardial infarction, heart failure, chronic kidney disease, dialysis, stroke, inpatient admi

207 e, moderate or severe ischemia, and advanced chronic kidney disease did not have substantial or susta

208 ary artery disease among individuals without chronic kidney disease during the 12.5-year follow-up pe

209 Acute and chronic kidney disease encompasses a complex set of dise

210 ons between PPI use and acute kidney injury, chronic kidney disease, end-stage renal disease, and ele

211 GRAIL was compared with the Chronic Kidney Disease Epidemiology Collaboration (CKD-E

212 Individuals with 2 or more Chronic Kidney Disease Epidemiology Collaboration (CKD-E

213 d glomerular filtration rate (eGFR) with the Chronic Kidney Disease Epidemiology Collaboration (CKD-E

214 n Study (CKiD) equation for children and the Chronic Kidney Disease Epidemiology Collaboration (CKD-E

215 ndomization to week 104, calculated with the Chronic Kidney Disease Epidemiology Collaboration creati

216 st error were observed with cystatin C-based chronic kidney disease epidemiology collaboration equati

217 glomerular filtration rate (eGFR) using the Chronic Kidney Disease Epidemiology Collaboration equati

218 al contribution to the future development of chronic kidney disease, ESKD, and mortality.

219 mellitus (glycated hemoglobin level, >=7%), chronic kidney disease (estimated glomerular filtration

220 aged 18-85 years with non-dialysis-dependent chronic kidney disease (estimated glomerular filtration

221 Eligible patients were those with chronic kidney disease (estimated glomerular filtration

222 t time of LTBI testing (e.g., HIV, diabetes, chronic kidney disease, etc.) were identified from physi

223 tudied in the treatment of heart failure and chronic kidney disease, even in patients without diabete

224 e (ESKD) in 4,843 participants of the German Chronic Kidney Disease (GCKD) study.

225 replication in 765,289 participants from the Chronic Kidney Disease Genetics (CKDGen) Consortium.

226 lomerular filtration rate and lowest rate of chronic kidney disease (>=stage 3) from year 1 onwards u

227 Patients with chronic kidney disease had elevated serum levels of IL-2

228 hoice of optimal chemotherapy and prognosis, chronic kidney disease has drawn attention in the treatm

229 e on patients with chronic heart failure and chronic kidney disease has identified hypochloremia as a

230 e general population, patients with advanced chronic kidney disease have a >10-fold higher burden of

231 Chronic kidney diseases have become a major issue worldw

232 tension, coronary artery disease, arthritis, chronic kidney disease, heart failure, stroke, asthma, c

233 h diabetes (HR, 1.95; 95% CI, 1.06-3.58) and chronic kidney disease (HR, 1.97; 95% CI, 1.05-3.67) eme

234 rrhythmias (HR: 1.62; 95% CI: 1.28 to 2.05), chronic kidney disease (HR: 2.41; 95% CI: 1.54 to 3.78),

235 es and established cardiovascular disease or chronic kidney disease, if kidney function is adequate.

236 d simple method of screening for the risk of chronic kidney disease in adults.

237 Using data from the Chronic Kidney Disease in Children (CKiD) study, we exam

238 The Chronic Kidney Disease in Children Study (CKiD) equation

239 The Chronic Kidney Disease in Children Study, a prospective

240 618 children and adolescents enrolled in the Chronic Kidney Disease in Children study, an observation

241 Chronic kidney disease in combination with anemia was th

242 fects and represent the most common cause of chronic kidney disease in the first three decades of lif

243 y tract (CAKUT) are the most common cause of chronic kidney disease in the first three decades of lif

244 disease in clinical trials of progression of chronic kidney disease in the setting of increased album

245 increased risk of cardiovascular disease and chronic kidney disease in those with gout, novel associa

246 ase III clinical trials for the treatment of chronic kidney disease in type 2 diabetes.

247 Biopsies from patients with chronic kidney disease, including AS were compared with

248 re urgently needed in patients with advanced chronic kidney disease, including those receiving dialys

249 d frequently occurs in patients with cancer, chronic kidney disease, infection, and many other illnes

250 ron deficiency, which include heart failure, chronic kidney disease, inflammatory bowel disease, pati

251 Chronic kidney disease is a common comorbid condition am

252 Chronic Kidney Disease is a growing problem across the w

253 Chronic kidney disease is a public health burden and it

254 Chronic kidney disease is associated with an increased r

255 Advanced chronic kidney disease is associated with further cortic

256 Although chronic kidney disease is associated with reduced graft

257 In patients with heart failure, chronic kidney disease is common and associated with a h

258 Chronic kidney disease is divided into 5 groups, ranging

259 sodium reabsorption during the initiation of chronic kidney disease is not established.

260 cal treatments for kidney disease - by 2040, chronic kidney disease is projected to be the fifth lead

261 Chronic kidney disease, lactate, ferritin, and fibrinoge

262 idney injury and those with risk factors for chronic kidney disease limit conclusions about safety in

263 Patients with advanced chronic kidney disease lose the capacity to fully excret

264 Prediction of development of chronic kidney disease (mGFR < 20 mL/min/1.73 m(2) , ini

265 displays multiple key features of late stage chronic kidney disease-mineral bone disorder (CKD-MBD),

266 therosclerosis, hypertension, heart failure, chronic kidney disease, obesity, and type 2 diabetes mel

267 idities, the most common being hypertension, chronic kidney disease, obstructive sleep apnoea, and me

268 dney repair after acute kidney injury and to chronic kidney disease of varied aetiologies, including

269 scular dysfunction may mediate the effect of chronic kidney disease on abnormal cardiac function and

270 dministrations in patients with stage 4 or 5 chronic kidney disease or undergoing dialysis, the upper

271 Conversely, chronic kidney disease (OR, 0.53) and invasive mechanica

272 aturation (OR, 0.94 [95% CI 0.93-0.96]), and chronic kidney disease (OR, 1.53 [95% CI 1.20-1.95]) wer

273 core of >=8 (p < 0.0001), anemia (p = 0.02), chronic kidney disease (p = 0.003), and higher N-termina

274 ic obstructive pulmonary disease (P = 0.73), chronic kidney disease (P = 0.09), and hearing loss (P =

275 Chronic kidney disease (P=0.02), prior cancer treatment

276 are effective for the treatment of anemia in chronic kidney disease patients and may also be benefici

277 In patients with resistant hypertension and chronic kidney disease, patiromer enabled more patients

278 s of 1-year mortality were old age, anaemia, chronic kidney disease, presence of valvular heart disea

279 CKD to kidney failure was assessed using the Chronic Kidney Disease Prognosis Consortium (CKD-PC) equ

280 dual-level data from eligible cohorts in the Chronic Kidney Disease Prognosis Consortium (CKD-PC) wit

281 Kidney fibrosis is the hallmark of chronic kidney disease progression; however, at present

282 c susceptibility of complex diseases such as chronic kidney disease remains challenging.

283 delivery approaches for acute kidney injury, chronic kidney disease, renal fibrosis, renovascular hyp

284 ellitus, hypertension, hypercholesterolemia, chronic kidney disease, smoking, and exercise.

285 cohort of patients with type 2 diabetes and chronic kidney disease, sTNFR1 predicted short-to-medium

286 dary Care Partnership to Improve Outcomes in Chronic Kidney Disease study.

287 daily for patients with or without advanced chronic kidney disease, supporting conventional dosing i

288 nces of obesity, diabetes, hypertension, and chronic kidney disease than white patients.

289 tion in patients over 60 years with advanced chronic kidney disease: the BiCARB RCT.

290 tcontrast acute kidney injury in adults with chronic kidney disease: the Kompas randomized clinical t

291 atients with type 2 diabetes and albuminuric chronic kidney disease to receive canagliflozin, an oral

292 nt diabetes, hypertension, dyslipidemia, and chronic kidney disease were investigated using survival

293 t males, hypertension, diabetes, obesity and chronic kidney disease were most frequent in the COVID-1

294 onstitutional disorders in adults, including chronic kidney disease, which affects more than 1 in 10

295 ular filtration rate (eGFR) in patients with chronic kidney disease who are at risk for progression i

296 testing in an African American patient with chronic kidney disease who is being evaluated for a kidn

297 f renal events in patients with diabetes and chronic kidney disease who were selected to optimise eff

298 scular events in patients with diabetes with chronic kidney disease with or without albuminuria have

299 In patients with diabetes and chronic kidney disease, with or without albuminuria, sot

300 lar events are prevalent among patients with chronic kidney disease without overt obstructive coronar